Cd73 Specific Sirna Loaded Chitosan Lactate Nanoparticles Potentiate the Antitumor Effect of a Dendritic Cell Vaccine in 4T1 Breast Cancer Bearing Mice Publisher Pubmed



Jadidiniaragh F^{1, 2, 3} ; Atyabi F^{4, 5} ; Rastegari A⁴ ; Kheshtchin N⁶ ; Arab S⁶ ; Hassannia H¹ ; Ajami M⁷ ; Mirsanei Z⁶ ; Habibi S⁶ ; Masoumi F⁶ ; Noorbakhsh F⁶ ; Shokri F¹ ; Hadjati J⁶
Source: Journal of Controlled Release Published:2017

Abstract

The efficacy of conventional anti-tumor immunotherapeutic approaches is markedly affected by the immunosuppressive microenvironment of tumor. Since adenosine is one of the main orchestra leaders in immunosuppression symphony of tumor, targeting its producing molecules such as CD73 can help to achieve a better clinical outcome following conventional cancer immunotherapeutic approaches. In the present study, we evaluated the efficacy of CD73-specific siRNA-loaded chitosan-lactate nanoparticles (ChLa NPs) in combination with tumor lysate pulsed dendritic cells (DCs) vaccine in treatment of 4T1 (murine derived) breast cancer bearing mice. Our results showed that intravenous administration of CD73-specific siRNA-loaded NPs led to reduced expression of CD73 in tumor cells which was associated with decreased tumor growth and metastasis, and improved mice survival. Furthermore, we found that the mechanism by which combination therapy inhibits tumor growth is in part related to downregulation of regulatory T (Treg), myeloid derived suppressor cells (MDSCs), and tumor associated macrophages, an augmented CTL effector function, improved proliferation status of T cells, increased production of inflammatory cytokines interferon (IFN)-γ and interleukin (IL)-17 and reduced levels of IL-10. Moreover, this treatment protocol attenuated the expression and activities of matrix metalloproteinases (MMPs) 2 and 9 which could be associated to the prevention of lung metastasis. In conclusion, our findings indicate that the use of CD73-specific siRNA-loaded NPs provides an immune potentiating function, thereby improves the efficacy of DC based cancer immunotherapy. © 2016 Elsevier B.V.